Pulsenmore

Company Overview

Snapshot

Founded in October 2014 by Elazar Sonnenschein, Pulsenmore operates with 51–200 employees. The company has raised $118.3 million across 6 funding rounds from 6 investors. In June 2021, Pulsenmore completed an Initial Public Offering on the TASE, raising $40 million.

Business overview

Pulsenmore develops universally accessible home ultrasound devices for remote care, enabling patients to self-scan by connecting their smartphones to a handheld ultrasound cradle. These scans are then automatically sent for remote clinical assessment by healthcare providers. The technology focuses on at-home prenatal ultrasound for remote assessment of fetal well-being, empowering women to proactively manage their pregnancies. Pulsenmore operates in the Health Tech & Life Sciences sector, specifically within medical devices and digital healthcare, serving markets in Israel, the United States, and Europe.

Strategic signal

In November 2025, Pulsenmore received FDA De Novo Marketing Authorization for its home-use prenatal ultrasound, marking a significant milestone for expanding its technology into the U.S. market. This authorization validates the company's innovative approach to remote prenatal care and signals strong potential for growth and adoption in a key healthcare market, positioning Pulsenmore as a leader in at-home medical diagnostics.

Company Intelligence Q&A

What was a significant recent commercial development for Pulsenmore?

In June 2024, Pulsenmore announced a strategic partnership with Ouma Health to expand access to remote prenatal care across the United States, indicating a focused effort on market penetration and collaboration in the U.S.

What recent leadership appointment did Pulsenmore make?

In June 2024, Pulsenmore appointed Len Farris as.

What regulatory milestone did Pulsenmore achieve in the U.S.?

In November 2025, Pulsenmore received FDA De Novo Marketing Authorization for its home-use prenatal ultrasound, pioneering a new era of prenatal care in the U.S. and enabling broader market access for its technology.

What was Pulsenmore's most recent funding activity?

In June 2026, Pulsenmore entered into a private placement with a single healthcare-focused institutional investor, raising $7.5 million.

What was a key strategic partnership for Pulsenmore in the U.S.?

In February 2026, Pulsenmore announced its first commercial engagement with a leading U.S.-based medical center, building U.S. momentum following FDA clearance and indicating initial market adoption.